Core Insights - The company reported a net sales of $1.04 billion for Q3 2025, a decrease of 4.1% year-over-year, primarily due to organic net sales decline and the impact of divestitures and exited products [7][13][20] - Despite challenges in the marketplace, the company achieved year-to-date EPS growth and margin expansion, indicating resilience in its operations [1][9] - A strategic review of the infant formula business has been initiated, alongside ongoing reviews of the oral care business, while the sale of the dermacosmetics business is on track for Q1 2026 [1][9] Year-to-Date Performance - Year-to-date net sales reached $3.14 billion, down 2.8% year-over-year, with organic net sales declining by 1.7% [7][29] - Adjusted EPS for the year is projected to be between $2.70 and $2.80, reflecting a growth of 5% to 9% year-over-year [38] Segment Highlights Consumer Self-Care Americas (CSCA) - CSCA net sales were $646 million, down 3.8%, with organic net sales also declining by 3.1% [21][22] - The segment experienced growth in the U.S. OTC business, driven by share gains in five of seven categories, despite overall soft market consumption [22][23] Consumer Self-Care International (CSCI) - CSCI net sales decreased by 4.5% to $398 million, with organic net sales down 5.3% [27][29] - The decline was attributed to soft total OTC category consumption and challenges in specific product categories, despite some share gains in key brands [29][30] Financial Metrics - Reported operating income for Q3 was $73 million, compared to $80 million in the prior year, with adjusted operating income at $173 million, down 4.9% [7][18] - The company reported a diluted EPS of $0.09, an improvement from a loss of $(0.13) in the prior year [20][24] Strategic Initiatives - The company is implementing Project Energize, aimed at enhancing operational efficiency and is expected to yield annualized pre-tax savings of $140 million to $170 million by the end of 2026 [11] - The strategic reviews and divestitures are part of a broader effort to streamline operations and focus on core business areas [1][9]

Core Viewpoint - Perrigo Company plc is initiating a strategic review of its infant formula business to assess various alternatives and align with its 'Three-S' plan, focusing on disciplined capital allocation and improving returns [1][2][4] Business Overview - The infant formula business is projected to generate net sales of approximately $360 million in 2025, representing about 90% of Perrigo's global Nutrition category and less than 10% of the company's total annual net sales [3] - The operations have stabilized, producing quality assured formula, and Perrigo remains the only large-scale U.S. store brand and contract manufacturer with a significant near-term innovation pipeline [3] Strategic Intent - The review aims to accelerate cash flows and reassess a previously announced investment of $240 million in the infant formula business while optimizing portfolio impact [2] - The CEO emphasized the need for discipline in positioning the company's portfolio for sustainable growth and free cash flow generation, noting that the external environment has changed, affecting the strategic fit with consumer health OTC businesses [4]

Core Insights - Perrigo Company plc is scheduled to participate in one-on-one investor meetings at the Jefferies Miami Consumer Conference on November 18, 2025, with President and CEO Patrick Lockwood-Taylor and CFO Eduardo Bezerra attending [1] Company Overview - Perrigo is a leading pure-play consumer health company with over a century of experience in providing high-quality health and wellness solutions primarily in North America and Europe [2] - The company is a pioneer in the over-the-counter (OTC) self-care market, offering trusted self-care solutions that do not require a prescription, ensuring accessibility and choice for consumers [2] Business Model - Perrigo's unique business model leverages complementary businesses, where cash-generative store brand private label offerings fuel investments for leading brands such as Opill, Mederma, Compeed, EllaOne, and Jungle Formula [3]

Core Insights - Perrigo Company plc is identified as one of the 12 cheap healthcare stocks to buy now [1] - The company specializes in over-the-counter and self-care products, generic prescription pharmaceuticals, and active pharmaceutical ingredients, with a strong presence in private-label consumer health products [2] Strategic Developments - Perrigo is advancing its strategic plan to "Stabilize, Streamline, and Strengthen" by divesting non-core businesses, including the sale of its Dermacosmetics branded business to KKR-managed Kairos Bidco AB for up to €327 million, expected to close in Q1 2026 [3] - This divestiture reflects the company's focus on its core self-care and private-label consumer health offerings [3] Leadership and Investor Engagement - Insider purchases by executives, including EVP Charles Atkinson and Chief Scientific Officer Lennox Abigail, totaling $23,200, indicate management's confidence in the company's growth prospects [4] - Senior management, including President and CEO Patrick Lockwood-Taylor, participated in the Barclays Global Consumer Staples Conference, emphasizing ongoing investor engagement and transparency regarding strategic direction and product pipeline [5]